Please assess the completion status of the following clinical trial:

Trial Title: A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 18 years old~* Patients must have been diagnosed with small-cell lung cancer (SCLC) and extensive disease~* ECOG performance status of 0, 1, or 2~* No prior systemic chemotherapy for the treatment of SCLC~Exclusion Criteria:~- Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMGN901 with carboplatin and etoposide (Type: EXPERIMENTAL): Patients will receive IMGN901 along with carboplatin and etoposide for up to 6 cycles and then be able to continue on IMGN901 alone until no further benefit or toxicity.
- Carboplatin and Etoposide (Type: ACTIVE_COMPARATOR): Patients will receive Carboplatin and etoposide for up to 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).